Grand mal seizure companies focus on developing medications and interventions for individuals experiencing grand mal seizures, a type of generalized tonic-clonic seizure associated with epilepsy. These companies contribute to the field of neurology by providing antiepileptic drugs and seizure management strategies to reduce the frequency and severity of grand mal seizures, improving the quality of life for individuals with epilepsy.
Eisai Co., Ltd. Launched their new AED, Fycompa (perampanel), in several countries for adjunctive treatment of partial seizures with or without secondary generalization. Investing in research on potential gene therapies and closed-loop stimulation systems for epilepsy management.
UCB Celltech Received FDA approval for Briviact (brivaracetam) for adjunctive treatment of partial-onset seizures in adults and adolescents. Collaborating with research institutions on developing new AEDs with enhanced efficacy and improved tolerability.
LivaNova Launched their VNS Therapy System, a vagus nerve stimulation device for drug-resistant epilepsy, with improved features and patient-friendly design. Partnering with healthcare providers to expand access to VNS therapy for eligible patients.
Medtronic Received FDA approval for their NeuroPace RNS® System, a responsive neurostimulation device for drug-resistant focal epilepsy. Focusing on developing closed-loop neuromodulation technologies for personalized seizure prediction and prevention.
Neuropace, Presented encouraging data at the American Epilepsy Society meeting on their investigational non-invasive vagus nerve stimulation device for seizure prevention. Partnering with pharmaceutical companies to explore potential synergies between neuromodulation and AED therapy.
Grand Mal Seizure Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)